-
Je něco špatně v tomto záznamu ?
Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus
MC. Brüggen, ST. Le, S. Walsh, A. Toussi, N. de Prost, A. Ranki, B. Didona, A. Colin, B. Horváth, E. Brezinova, B. Milpied, C. Moss, C. Bodemer, D. Meyersburg, C. Salavastru, GS. Tiplica, E. Howard, E. Bequignon, JN. Bouwes Bavinck, J. Newman, J....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
33657677
DOI
10.1111/bjd.19893
Knihovny.cz E-zdroje
- MeSH
- dítě MeSH
- dospělí MeSH
- konsensus MeSH
- lidé MeSH
- retrospektivní studie MeSH
- Stevensův-Johnsonův syndrom * diagnóza terapie MeSH
- výzkum MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Supportive care is the cornerstone of management of adult and paediatric Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). However, consensus on the modalities of supportive care is lacking. OBJECTIVES: Our aim in this international multicentric Delphi exercise was to establish a multidisciplinary expert consensus to standardize recommendations regarding supportive care in the acute phase of SJS/TEN. METHODS: Participants were sent a survey via the online tool SurveyMonkey, consisting of 103 statements organized into 11 topics: multidisciplinary team composition, suspect drug management, infection prevention, fluid resuscitation and prevention of hypothermia, nutritional support, pain and psychological distress management, management of acute respiratory failure, local skincare, ophthalmological management, management of other mucosa, and additional measures. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). The results were analysed according to the RAND/UCLA Appropriateness Method. RESULTS: Forty-five participants from 13 countries (on three continents) participated. After the first round, a consensus was obtained for 82.5% of the 103 initially proposed statements. After the second round, a final consensus was obtained for 102 statements. CONCLUSIONS: We have reached an international Delphi-based consensus on best supportive care practice for SJS/TEN. Our expert consensus should help guide physicians in treating patients with SJS/TEN and thereby improve short-term prognosis and the risk of sequelae.
Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA
Birmingham Children's Hospital and University of Birmingham Birmingham UK
Christine Kühne Center for Allergy Research and Education Davos Switzerland
Clinical Experimental Sciences Faculty of Medicine University of Southampton Southampton UK
Department of Dermatology Aarhus University Hospital Palle Juul Jensens Aarhus Denmark
Department of Dermatology and Allergy University Hospital of Munich LMU Munich Germany
Department of Dermatology AP HP Necker Hospital Paris France
Department of Dermatology Brigham and Women's Hospital Harvard Medical School Boston MA USA
Department of Dermatology CHU Bordeaux Bordeaux France
Department of Dermatology CHU Charles Nicolle Rouen France
Department of Dermatology King's College Hospital London UK
Department of Dermatology Kyorin University School of Medicine Tokyo Japan
Department of Dermatology Leiden University Medical Center Leiden the Netherlands
Department of Dermatology Perelman School of Medicine University of Pennsylvania Philadelphia PA USA
Department of Dermatology University Hospital Zurich Zurich Switzerland
Department of Dermatology University of California Davis Sacramento CA USA
Department of Dermatology University of California San Francisco CA USA
Department of Medicine and Pharmacology Vanderbilt University Medical Center Nashville TN USA
Department of Psychiatry AP HP Henri Mondor Albert Chenevier Hospitals Cr France
Dermatology Department AP HP Henri Mondor Hospital Créteil France
Division of Clinical Pharmacology and Toxicology University of Toronto Toronto ON Canada
Division of Dermatology Department of Internal Medicine Ohio State University Columbus OH USA
Division of Dermatology Sunnybrook Health Sciences Centre Toronto ON Canada
Faculty of Medicine University of Zurich Zurich Switzerland
Intensive Care Unit AP HP Henri Mondor Hospital Créteil France
Keck USC School of Medicine Los Angeles CA USA
Macmillan Skin Cancer CNS Normanby Building Denmark Hill London UK
Massachusetts General Hospital Harvard Medical School Boston MA USA
Niigata University Graduate School of Medical and Dental Sciences Niigata Japan
Ophthalmology Department Hospital Charles Nicolle EA7510 UFR Santé Rouen University Rouen France
Réanimation Chirurgicale et des Brûlés PTMC CHU Nantes Nantes France
ToxiTEN Group European Reference Network for Rare Skin Diseases Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21024992
- 003
- CZ-PrNML
- 005
- 20211026134225.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjd.19893 $2 doi
- 035 __
- $a (PubMed)33657677
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Brüggen, M-C $u Department of Dermatology, University Hospital Zurich, Zurich, Switzerland $u Faculty of Medicine, University of Zurich, Zurich, Switzerland $u Christine Kühne Center for Allergy Research and Education, Davos, Switzerland $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France
- 245 10
- $a Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus / $c MC. Brüggen, ST. Le, S. Walsh, A. Toussi, N. de Prost, A. Ranki, B. Didona, A. Colin, B. Horváth, E. Brezinova, B. Milpied, C. Moss, C. Bodemer, D. Meyersburg, C. Salavastru, GS. Tiplica, E. Howard, E. Bequignon, JN. Bouwes Bavinck, J. Newman, J. Gueudry, M. Nägeli, K. Zaghbib, K. Pallesen, A. Bygum, P. Joly, P. Wolkenstein, SL. Chua, R. Le Floch, NH. Shear, CY. Chu, N. Hama, R. Abe, WH. Chung, T. Shiohara, M. Ardern-Jones, P. Romanelli, EJ. Phillips, RS. Stern, J. Cotliar, RG. Micheletti, A. Brassard, JT. Schulz, RP. Dodiuk-Gad, AR. Dominguez, AS. Paller, L. Seminario-Vidal, A. Mostaghimi, MH. Noe, S. Worswick, D. Tartar, R. Sheridan, BH. Kaffenberger, K. Shinkai, E. Maverakis, LE. French, S. Ingen-Housz-Oro
- 520 9_
- $a BACKGROUND: Supportive care is the cornerstone of management of adult and paediatric Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). However, consensus on the modalities of supportive care is lacking. OBJECTIVES: Our aim in this international multicentric Delphi exercise was to establish a multidisciplinary expert consensus to standardize recommendations regarding supportive care in the acute phase of SJS/TEN. METHODS: Participants were sent a survey via the online tool SurveyMonkey, consisting of 103 statements organized into 11 topics: multidisciplinary team composition, suspect drug management, infection prevention, fluid resuscitation and prevention of hypothermia, nutritional support, pain and psychological distress management, management of acute respiratory failure, local skincare, ophthalmological management, management of other mucosa, and additional measures. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). The results were analysed according to the RAND/UCLA Appropriateness Method. RESULTS: Forty-five participants from 13 countries (on three continents) participated. After the first round, a consensus was obtained for 82.5% of the 103 initially proposed statements. After the second round, a final consensus was obtained for 102 statements. CONCLUSIONS: We have reached an international Delphi-based consensus on best supportive care practice for SJS/TEN. Our expert consensus should help guide physicians in treating patients with SJS/TEN and thereby improve short-term prognosis and the risk of sequelae.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a výzkum $7 D012106
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a Stevensův-Johnsonův syndrom $x diagnóza $x terapie $7 D013262
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Le, S T $u Department of Dermatology, University of California, Davis, Sacramento, CA, USA
- 700 1_
- $a Walsh, S $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Department of Dermatology, King's College Hospital, London, UK
- 700 1_
- $a Toussi, A $u Department of Dermatology, University of California, Davis, Sacramento, CA, USA
- 700 1_
- $a de Prost, N $u Intensive Care Unit, AP-HP, Henri Mondor Hospital, Créteil, France $u Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France
- 700 1_
- $a Ranki, A $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Department of Skin and Allergic Diseases, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
- 700 1_
- $a Didona, B $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u First Dermatology Division, Institute Dermopatico dell'Immacolata (I.D.I.) - IRCCS, Via Monti di Creta 104, Rome, 00167, Italy
- 700 1_
- $a Colin, A $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
- 700 1_
- $a Horváth, B $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 700 1_
- $a Brezinova, E $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Department of Dermatovenereology, St Ann's University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Milpied, B $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Department of Dermatology, CHU Bordeaux, Bordeaux, France
- 700 1_
- $a Moss, C $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Birmingham Children's Hospital and University of Birmingham, Birmingham, UK
- 700 1_
- $a Bodemer, C $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Department of Dermatology, AP-HP, Necker Hospital, Paris, France
- 700 1_
- $a Meyersburg, D $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University Salzburg, Salzburg, Austria
- 700 1_
- $a Salavastru, C $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Department of Paediatric Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Tiplica, G-S $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Department of Dermatology II, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Howard, E $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Birmingham Children's Hospital and University of Birmingham, Birmingham, UK
- 700 1_
- $a Bequignon, E $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Department of Otorhinolaryngology and Head and Neck Surgery, AP-HP, Henri Mondor Hospital, Créteil, France
- 700 1_
- $a Bouwes Bavinck, J N $u Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands
- 700 1_
- $a Newman, J $u Macmillan Skin Cancer CNS, Normanby Building, Denmark Hill, London, UK
- 700 1_
- $a Gueudry, J $u Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Ophthalmology Department, Hospital Charles Nicolle, EA7510, UFR Santé, Rouen University, Rouen, France
- 700 1_
- $a Nägeli, M $u Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a Zaghbib, K $u Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Department of Psychiatry, AP-HP, Henri Mondor-Albert Chenevier Hospitals, Cr, France
- 700 1_
- $a Pallesen, K $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Department of Dermatology, Aarhus University Hospital, Palle Juul-Jensens, Aarhus, Denmark
- 700 1_
- $a Bygum, A $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Clinical Institute, University of Southern Denmark, Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
- 700 1_
- $a Joly, P $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Department of Dermatology, CHU Charles, Nicolle, Rouen, France
- 700 1_
- $a Wolkenstein, P $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France
- 700 1_
- $a Chua, S-L $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Queen Elizabeth Hospital Birmingham, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
- 700 1_
- $a Le Floch, R $u Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Réanimation Chirurgicale et des Brûlés, PTMC, CHU Nantes, Nantes, France
- 700 1_
- $a Shear, N H $u Division of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada $u Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- 700 1_
- $a Chu, C-Y $u Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
- 700 1_
- $a Hama, N $u Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 700 1_
- $a Abe, R $u Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 700 1_
- $a Chung, W-H $u Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- 700 1_
- $a Shiohara, T $u Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
- 700 1_
- $a Ardern-Jones, M $u Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
- 700 1_
- $a Romanelli, P $u Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA
- 700 1_
- $a Phillips, E J $u Department of Medicine & Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA
- 700 1_
- $a Stern, R S $u Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Cotliar, J $u Science 37, Los Angeles, CA, USA
- 700 1_
- $a Micheletti, R G $u Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- 700 1_
- $a Brassard, A $u Department of Dermatology, University of California, Davis, Sacramento, CA, USA
- 700 1_
- $a Schulz, J T $u Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Dodiuk-Gad, R P $u Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- 700 1_
- $a Dominguez, A R $u Department of Dermatology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
- 700 1_
- $a Paller, A S $u Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- 700 1_
- $a Seminario-Vidal, L $u Department of Dermatology, University of South Florida, Cutaneous Oncology Program, Moffitt Cancer Center, Tampa, FL, USA
- 700 1_
- $a Mostaghimi, A $u Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Noe, M H $u Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Worswick, S $u Keck-USC School of Medicine, Los Angeles, CA, USA
- 700 1_
- $a Tartar, D $u Department of Dermatology, University of California, Davis, Sacramento, CA, USA
- 700 1_
- $a Sheridan, R $u Burn Surgery Service, Shriners Burns Hospital, Sumner Redstone Burn Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Kaffenberger, B H $u Division of Dermatology, Department of Internal Medicine, Ohio State University, Columbus, OH, USA
- 700 1_
- $a Shinkai, K $u Department of Dermatology, University of California, San Francisco, CA, USA
- 700 1_
- $a Maverakis, E $u Department of Dermatology, University of California, Davis, Sacramento, CA, USA
- 700 1_
- $a French, L E $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK $u Department of Dermatology and Allergy, University Hospital of Munich, LMU, Munich, Germany
- 700 1_
- $a Ingen-Housz-Oro, S $u ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France $u Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France $u Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France $u Universit, EpiDermE, Créteil, France
- 773 0_
- $w MED00009371 $t The British journal of dermatology $x 1365-2133 $g Roč. 185, č. 3 (2021), s. 616-626
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33657677 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026134231 $b ABA008
- 999 __
- $a ok $b bmc $g 1714161 $s 1145499
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 185 $c 3 $d 616-626 $e 20210427 $i 1365-2133 $m British journal of dermatology $n Br J Dermatol $x MED00009371
- LZP __
- $a Pubmed-20211013
